drugset / Trial / NCT00533026

Duloxetine - Warfarin Pharmacodynamic Study

NCT00533026

Phase 1 Completed 60 enrolled Eli Lilly and Company
RandomizedSingle-groupOpen-labelBasic science

Summary

To evaluate the blood clotting effects of multiple doses of warfarin at steady state when taken at the same time as multiple doses of duloxetine as measured by changes in the International Normalised Ratio. All subjects will begin dosing with warfarin, then after approximately 12 days, duloxetine 60 mg is added and subjects with stabilized INR will either continue dosing at 60 mg or have a dose increase to 120 mg.

Timeline

Start
2007-07
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 60 mg Oral
Comparator Duloxetine Small molecule 120 mg Oral
Comparator Warfarin Small molecule Oral

Indications

No indication recorded.